Minneapolis MN (January 25, 2023) – Imricor Medical Systems, Inc. (ASX:IMR) Imricor, the global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation products, is pleased to announce that it has entered into a Memorandum of Understanding (MOU) with GE HealthCare.

At the Helios Klinikum Berlin-Buch, catheter ablation was performed using a cardiac MRI. For the first time, a team of cardiologists has paired the standard procedure of catheter ablation with a cardiac MRI. In the future, this new method promises to improve the treatment of complex cardiac arrhythmias through real-time imaging and more precise treatment of heart tissue. The head of the Heart Rhythm Center Berlin/Brandenburg at the Helios Klinikum Berlin-Buch Dr. med. Michael Wiedemann explains the innovative process in an interview. 

22 September 2022 – Minneapolis, MN United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR), the global leader in real-time iCMR cardiac ablation products, is pleased to announce that the Company has submitted for approval to commence a real-time iCMR-guided ventricular tachycardia (VT) ablation clinical trial.

11 August 2022 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in realtime interventional cardiac magnetic resonance (iCMR) cardiac ablation products, is pleased to announce it has entered into two new agreements with Siemens Healthineers that together provide Imricor the ability to deploy the Company’s new 3D mapping system on the Siemens Healthineers Magnetic Resonance Imaging (MRI) platform.

31 March 2022 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in Realtime iCMR cardiac ablation products, is pleased to announce it has entered into a Development Agreement with Mammendorfer Institut für Physik und Medizin GmbH (MIPM), a leading developer and manufacturer of MRI-compatible medical devices, including an MRI-compatible external cardioverter defibrillator. MIPM is headquartered in Mammendorf, Germany. Performing cardiac ablation of complex arrythmia, such as VT, requires an external cardioverter defibrillator. MIPM has developed such a system.  Imricor’s Vice President of Marketing and Business Development, Nick Twohy, said: “We are thrilled to be aligned with a world leader in providing MRI-compatible devices. MIPM’s defibrillator and technology are critical to the success of performing complex iCMR ablations.” Under the terms of the agreement, Imricor and MIPM will collaborate on product development and clinical trials, including Imricor’s upcoming trial for expanded indications to VT ablation procedures in the iCMR. Andreas Klement, Vice President, MIPM, stated, “MIPM is very happy about the cooperation with Imricor and expects a long-term and fruitful cooperation in this innovative field of electrophysiological examinations and ablation procedures in the MR-Environment.”

11 February 2022 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in realtime iCMR cardiac ablation products, today announced the scheduled retirement of its Chief Financial Officer, Ms Lori Milbrandt, and the appointment of Mr Jonathon Gut as the incoming Chief Financial Officer.

4 January 2022 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in realtime iCMR cardiac ablation products, is pleased to announce that the Henry Dunant Hospital Centre in Athens, Greece (https://www.dunant.gr/en/) is the latest institution to adopt Imricor’s iCMR ablation solutions.

28 December 2021 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in realtime iCMR cardiac ablation products, is pleased to announce that the German Heart Centre Berlin (https://www.dhzb.de/en/), and the Charité Medical University, Virchow-Klinikum Campus (Charité) (https://www.charite.de/en/), both in Berlin, Germany, are the latest two institutions to adopt Imricor’s iCMR ablation solutions.

13 October 2021 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in iCMR-guided cardiac ablation products, is pleased to announce that the Semmelweis University Heart and Vascular Centre in Budapest Hungary, has signed a purchase agreement with Imricor, making it the eleventh site to establish an iCMR lab to perform ablations with Imricor’s products.

30 August 2021 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided cardiac ablation products, is pleased to announce it has entered into a Sales Distribution Agreement with NordicNeuroLab AS, a leading maker of MRI compatible in-room monitors, headquartered in Norway.